Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs ENTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 46.2 HOLD), While ENTA Leads 3–2 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: DMAC 2 – 3 ENTA (1 Tie) Matrix Metrics: DMAC 5 – 4 ENTA

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (46.3/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 5–4 (led by Growth & Scale, Profitability & Quality), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.39 (N/M Forward P/E, 0.0% operating margin) versus ENTA at $10.79 (44.0x Forward P/E, -90.0% operating margin).

  • Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.72β · 97% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs ENTA
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.39
-4.55% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.72β · 97% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88

6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 3 ENTA)

Columns: Metric · DMAC · ENTA
1. Valuation Multiples ENTA
Forward P/E N/M 44.0x
Trailing P/E N/M 44.0x
PEG Ratio N/M N/M
EV / Revenue N/M 5.3x
2. Growth & Scale DMAC
Revenue Growth (YoY) +0.0% -21.6%
Earnings Growth (YoY) +0.0% -66.2%
TTM Revenue (USD) N/A $65M
Market Cap $503.1M $326.2M
3. Profitability & Quality DMAC
Gross Margin N/A 100.0%
Operating Margin 0.0% -90.0%
Net Profit Margin 0.0% -96.9%
Return on Equity (ROE) -114.6% -70.1%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$32M -$37M
Cash Flow Margin N/A -56.6%
Net Cash / Leverage $4.9M Net Cash $22M Net Debt (0.55x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTA
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 106.3% (14th %ile) 78.7% (11th %ile)
Put/Call OI Skew N/A 0.31x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (5) vs ENTA (4)
Institutional Metric DMAC ENTA Criterion Row Edge
Market Capitalization
Scale
$503.1M $326.2M Larger Scale DMAC
Trailing P/E Ratio
Valuation
N/M 44.0x Lower Multiple ENTA
Forward P/E Ratio
Valuation
N/M 44.0x Lower Multiple ENTA
Revenue Growth (YoY)
Growth
+0.0% -21.6% Higher Growth DMAC
Operating Margin (TTM)
Profitability
0.0% -90.0% Higher Margin DMAC
Net Profit Margin
Profitability
0.0% -96.9% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-114.6% -70.1% Higher ROE ENTA
52-Week Range Position
Momentum
55% ($5–$11) 10% ($10–$17) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.72β · 97% Vol 0.89β · 58% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 46.2 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
N/A $65M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$37M ($22M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +13.62 pp
DMAC: +10.83% · ENTA: -2.79%
3M Horizon DMAC +45.8 pp
DMAC: +26.93% · ENTA: -18.87%
6M Horizon DMAC +67.49 pp
DMAC: +47.71% · ENTA: -19.78%
1Y Horizon DMAC +62.74 pp
DMAC: +54.8% · ENTA: -7.94%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DMAC Revenue ENTA Revenue DMAC Op. Margin ENTA Op. Margin Margin Leader
FY2018 $0M $210M -1352.2% 42.7% ENTA
FY2019 N/A $210M N/A 17.9% ENTA
FY2020 N/A $120M N/A -34.0% ENTA
FY2021 N/A $100M N/A -112.9% ENTA
FY2022 N/A $90M N/A -143.7% ENTA
FY2023 N/A $80M N/A -173.2% ENTA
FY2024 N/A $70M N/A -179.9% ENTA
FY2025 N/A $70M N/A -130.7% ENTA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs ENTA Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (46.3/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 5–4 (led by Growth & Scale, Profitability & Quality), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.39 (N/M Forward P/E, 0.0% operating margin) versus ENTA at $10.79 (44.0x Forward P/E, -90.0% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.72β · 97% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DMAC leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while ENTA shifted -66.7%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.

ENTA screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus ENTA (-70.1% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.72β · 97% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.